08/11/2025 03:12
|
Medical, Health & Aged Care
− Phase 1b, Open-Label Study Follow Up Shows Stable Kidney Function (eGFR) in Patients Treated with Investigational Mezagitamab Through Week 96 – 18 Months After Last Dose1
− Rapid Reductions in...